1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Cancer Drug News 26 OCTOBER 2015

Cancer Drug News 26 OCTOBER 2015

  • October 2015
  • -
  • Espicom Business Intelligence
  • -
  • 12 pages

Industry Trend Analysis - Optimal Legacy/Innovation Balance To Maintain Roche's Growth Trajectory
Industry Brief - Spectrum Receives Evomela CRL From FDA
Industry Brief - Synta Terminates Ganetespib Phase III Trial In Lung Cancer
Industry Brief - Exelixis Initiates Cabozantinib Rolling NDA Submission For RCC In US
Industry Brief - Atara Bio's Activin Inhibitor Gains FDA ODD For OC
Industry Brief - MacroGenics/Merck Enter Immuno-Oncology Clinical Trial Collaboration
Industry Brief - Onivyde Approved In Taiwan For MPC
Industry Brief - Amgen Gains Positive CHMP Positive For Imlygic
Industry Brief - FDA Approves Yondelis For LPS/LMS
Industry Trend Analysis - Collaborative Approach Will Bolster AstraZeneca/Lilly's Immuno-Oncology Presence
Industry Brief - NW Bio Raises Funds To Advance DCVax-L/DCVax-Direct Programmes
Industry Trend Analysis - Greater Knowledge Application Boosting Cancer Vaccine Potential
Industry Brief - Nuevolution/Janssen Enter Drug Discovery Collaboration
Industry Brief - Symphogen Raises Funds To Advance Oncology Pipeline
Industry Trend Analysis - Novartis Maximising Chances Of Immuno-oncology Success
Industry Brief - Cancer Conferences - January 2016

Table Of Contents

Cancer Drug News 26 OCTOBER 2015

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Hematological Cancers: Analytical Tool

Hematological Cancers: Analytical Tool

  • $ 11505
  • Industry report
  • August 2016
  • by Bioseeker

Analytical Tools are cancer area specific intelligence and surveillance toolkits within a select number of hot, emerging cancer therapy areas. They are designed to empower biotech/pharma professionals ...

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation

  • $ 6995
  • Industry report
  • September 2016
  • by GBI Research

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation Summary Glioblastoma multiforme (GBM) is a grade IV tumor that arises from astrocytes. It is ...

Drugs and Diagnostics for Hematological Disorders: Global Markets

Drugs and Diagnostics for Hematological Disorders: Global Markets

  • $ 6650
  • Industry report
  • September 2016
  • by BCC Research

Use this report to: - Receive detailed information regarding screening, testing and treatment options for hematological disorders and blood cancer. - Learn about the types of diagnostic and treatment ...

Lung Cancer: Analytical Tool

August 2016 $ 8096

Ovarian Cancer: Analytical Tool

August 2016 $ 8096

Renal Cancer: Analytical Tool

August 2016 $ 8096

Bladder Cancer: Analytical Tool

August 2016 $ 8096

ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.